• Acarix flagged a peer-reviewed PLOS Digital Health study showing its CADScor acoustic platform can detect heart failure in addition to coronary disease.
• Results have already been published, supporting performance comparable to a standard blood test while generating fewer false positive referrals.
• Findings suggest the tool could help triage suspected heart failure patients faster, potentially reducing demand for echocardiography in low-risk cases.
• The heart failure algorithm remains investigational, not covered by current CE mark or FDA clearance, requiring larger external validation before regulatory filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acarix AB published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.